Share on StockTwits

Albany Molecular Research (NASDAQ:AMRI) Director Ambra Thomas E. Phd D unloaded 20,000 shares of the stock on the open market in a transaction that occurred on Thursday, July 10th. The stock was sold at an average price of $20.94, for a total transaction of $418,800.00. Following the transaction, the director now directly owns 2,821,879 shares of the company’s stock, valued at approximately $59,090,146. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Albany Molecular Research (NASDAQ:AMRI) traded up 1.19% on Monday, hitting $21.25. 242,931 shares of the company’s stock traded hands. Albany Molecular Research has a 52 week low of $9.71 and a 52 week high of $22.30. The stock has a 50-day moving average of $18.92 and a 200-day moving average of $15.53. The company has a market cap of $668.5 million and a price-to-earnings ratio of 69.31.

Albany Molecular Research (NASDAQ:AMRI) last released its earnings data on Tuesday, May 6th. The company reported $0.16 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.23 by $0.07. The company had revenue of $51.00 million for the quarter, compared to the consensus estimate of $62.19 million. Analysts expect that Albany Molecular Research will post $0.92 EPS for the current fiscal year.

A number of research firms have recently commented on AMRI. Analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Separately, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.

Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.